CD274 and non-small cell lung carcinoma: In a meta-analysis of randomized controlled trials comparing anti-PD-1/PD-L1 monotherapy and chemotherapy in the treatment of advanced NSCLC, Khan et al selected 7 trials and revealed a better OS, PFS, and objective response rate (ORR) for ICI (pooled HRs of 0.72 (P < .00001), 0.84 (P < .02) and odds ratio 1.52 (P < .02), respectively).